ZIOPHARM Oncology Inc Stock News

ZIOPHARM Oncology, Inc. (ZIOP) CEO Laurence Cooper on Q4 2020 Results - Earnings Call Transcript

Company to Hold R&D Day on Thursday, March 11, 2021 Company to Hold R&D Day on Thursday, March 11, 2021

An ugly board of directors skirmish came to an end.

BOSTON, Feb. 05, 2021 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (“Ziopharm” or “the Company”) (Nasdaq:ZIOP) today announced the election of Robert Postma to its Board of Directors (the “Bo

BOSTON, Dec. 23, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (“Ziopharm” or “the Company”) (Nasdaq: ZIOP), today announced that Laurence Cooper, M.D., Ph.D., Chief Executive Officer of Zi

– Advances Eden BioCell's clinical program to validate Rapid Personalized Manufacturing (RPM) –

Investors need to pay close attention to Ziopharm (ZIOP) stock based on the movements in the options market lately.

Jaime Vieser and Holger Weis Elected to Board of Directors Jaime Vieser and Holger Weis Elected to Board of Directors

BOSTON, Dec. 14, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (Nasdaq: ZIOP) (“Ziopharm” or the “Company”), today announced that Satyavrat “Sath” Shukla, CFA, Chief Financial Officer,

NEW YORK--(BUSINESS WIRE)--WaterMill Asset Management Corp. (together with its affiliates, “WaterMill” or “we”) today responded to the latest element of the low-road campaign that Ziopharm Onc

Ziopharm Recommends Shareholders Return the GREEN Consent Revocation Card

Recommends A gainst E lecting WaterMill Nominee Jaime Vieser

NEW YORK--(BUSINESS WIRE)--WaterMill Asset Management Corp. (together with its affiliates, “WaterMill” or “we”), which collectively with the other participants in its consent solicitation bene

Has Held Several Discussions with WaterMill to Reach an Amicable Resolution to Consent Solicitation

NEW YORK--(BUSINESS WIRE)--WaterMill Asset Management Corp. (together with its affiliates, “WaterMill” or “we”) today announced that Glass, Lewis & Co., LLC (“Glass Lewis”), a leading prox